报价延迟最少15分钟:2024/11/15 21:50 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.82 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.57/1.22
|
|
企业价值
53.00B
|
| 资产负债 |
|
每股账面净值
5.31
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
15.44B
|
|
每股收益
8.05
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/11/15 21:50 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space,including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power. |